Vycor Medical, Inc. (OTCQB: VYCO) announced its financial results for the year ended December 31, 2025, showcasing a revenue increase of 17% compared to the previous year. The company reported total revenue of $1,863,400, with the Vycor Medical division generating $1,796,070, marking an 18% growth driven primarily by international sales. The gross profit for the year was $1,498,295, reflecting an 11% increase over 2024, although the gross margin decreased to 83% from 89% due to higher manufacturing costs and a shift towards international sales. Notably, the company achieved an operating profit of $33,900, a significant turnaround from an operating loss of $(9,145) in 2024. Additionally, non-GAAP operating profit rose to $145,881, compared to $81,548 in the previous year. The report highlights the company's commitment to innovation in neurosurgery and vision rehabilitation, with ongoing developments in its product lines, including the ViewSite Brain Access System (VBAS) and NovaVision therapies. The financial results reflect a positive operational execution and strategic outlook, positioning Vycor Medical for continued growth in the medical device market.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.